Cantor Fitzgerald Increases Earnings Estimates for Prothena

Prothena Corporation plc (NASDAQ:PRTA) – Stock analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for Prothena in a research report issued on Monday, November 10th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the biotechnology company will post earnings of $0.39 per share for the year, up from their prior estimate of ($0.25). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Prothena (NASDAQ:PRTA) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.07). Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%. The company had revenue of $2.42 million for the quarter, compared to analyst estimates of $6.64 million.

PRTA has been the topic of a number of other research reports. Piper Sandler increased their price objective on Prothena from $15.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, October 28th. Wall Street Zen raised shares of Prothena from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright upped their price objective on shares of Prothena from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, November 7th. JMP Securities lowered their target price on shares of Prothena from $29.00 to $11.00 and set a “market outperform” rating on the stock in a research note on Tuesday, September 2nd. Finally, Chardan Capital restated a “buy” rating and set a $18.00 price target on shares of Prothena in a report on Thursday, August 28th. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $25.78.

Prothena Price Performance

NASDAQ:PRTA traded up $0.17 during mid-day trading on Wednesday, reaching $10.65. The stock had a trading volume of 37,425 shares, compared to its average volume of 973,888. The stock has a market cap of $573.45 million, a P/E ratio of -1.89 and a beta of -0.09. Prothena has a fifty-two week low of $4.32 and a fifty-two week high of $17.94. The business’s 50 day moving average is $9.58 and its 200 day moving average is $7.80.

Hedge Funds Weigh In On Prothena

A number of hedge funds have recently modified their holdings of PRTA. Acadian Asset Management LLC acquired a new stake in Prothena in the 2nd quarter valued at $6,176,000. Rangeley Capital LLC bought a new stake in shares of Prothena in the 2nd quarter worth about $4,342,000. Federated Hermes Inc. increased its position in shares of Prothena by 116.2% during the 2nd quarter. Federated Hermes Inc. now owns 1,181,087 shares of the biotechnology company’s stock worth $7,169,000 after purchasing an additional 634,832 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Prothena by 479.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 735,765 shares of the biotechnology company’s stock valued at $7,181,000 after purchasing an additional 608,814 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in Prothena in the second quarter valued at about $3,495,000. 97.08% of the stock is owned by institutional investors and hedge funds.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.